CombiMatrix Rebuffed, Hyseq Remains in Favor in Bid for Variangenics

Jan 21, 2003

NEW YORK, Jan. 21 - Hyseq's bid to buy Variagenics is still a go after the attention of another suitor was rebuffed, Variagenics said today.

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.